Glycaemic control with liraglutide: the phase 3 trial programme.
about
The clinical development program of lixisenatide: a once-daily glucagon-like Peptide-1 receptor agonist.Liraglutide in adults with type 2 diabetes: global perspective on safety, efficacy and patient preference.Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes.Glucagon-like peptide-1 analogues: An overview.Using albumin to improve the therapeutic properties of diabetes treatments.Clinical experience with Liraglutide in 196 patients with type 2 diabetes from a tertiary care center in India.
P2860
Glycaemic control with liraglutide: the phase 3 trial programme.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Glycaemic control with liraglutide: the phase 3 trial programme.
@en
Glycaemic control with liraglutide: the phase 3 trial programme.
@nl
type
label
Glycaemic control with liraglutide: the phase 3 trial programme.
@en
Glycaemic control with liraglutide: the phase 3 trial programme.
@nl
prefLabel
Glycaemic control with liraglutide: the phase 3 trial programme.
@en
Glycaemic control with liraglutide: the phase 3 trial programme.
@nl
P1476
Glycaemic control with liraglutide: the phase 3 trial programme.
@en
P2093
P356
10.1111/J.1742-1241.2010.02496.X
P577
2010-10-01T00:00:00Z